All lobbying filings
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. filed a Q1 report for Sarepta Therapeutics, Inc. on April 20, 2026.
Lobbying for Sarepta Therapeutics, Inc.
Filing · LD-2 quarterly report
Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$270,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
California
Lobbyists on this filing
1
-
MADISON SMITH Former member of Congress New on this filingPreviously held: Staff Assistant, Rep. Jerry Lewis; Staff Assistant, Rep. Ken Calvert
Government bodies contacted
2
Lobbying activity
2
Duchenne Muscular Dystrophy and Rare Disease Patient Access to Treatments Newborn Screening for Rare Diseases
Scientific Innovation in Healthcare Gene Therapies Artificial Intelligence and Data Governance